ClinicalTrials.gg
RecruitingNCT07521202IMPACT PTUpdated Nov 4, 2026

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

An interventional study of Standardized patient coaching in HR+/HER2- Early Breast Cancer, sponsored by Institut fuer Frauengesundheit. Recruiting at 8 sites in Germany. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institut fuer Frauengesundheit · Not applicable, Interventional, and Supportive care

How we know · 2 judgments

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
257
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.

Started
2026
with 1 other
No phase
2 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is one of 2 that started in 2026, is one of 2 with no phase, and was the 8th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, or all of them as a file.
02

Study summary

The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.

The main question it aims to answer is, whether standardized coaching leads to patients taking abemaciclib much more consistently. Researchers will therefore compare therapy adherence of patients receiving standardized coaching to patients receiving routine care.

Participants will be asked to answer several questionnaires.

03

Conditions studied

  • HR+/HER2- Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women age 18 or older at time of ICF signature
  • Patients with HRpos/HER2neg early breast cancer who are treated with oral, commercially available prescribed abemaciclib in combination with endocrine therapy. Patients can be included if abemaciclib therapy was started no more than 28 days ago
  • Patients treated with abemaciclib according to the SmPC and each center´s medical practice
  • given prior to the starting study activities

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Patients with against abemaciclib according to the current SmPC
  • Patients who are not eligible for the study due to severe comorbidities, unavailability or any other relevant reason according to the treating physician
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
257 participants (estimated)

Study arms

  • Experimental
    Standardized patient coaching

    Patients receive standardized coaching based on the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool© (MOATT)

    Behavioral: Standardized patient coaching

Interventions

  • BehavioralStandardized patient coaching

    Standardized patient coaching based on the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool© (MOATT)

This study also gives AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time to discontinuation

    Time to permanent discontinuation of abemaciclib therapy

    Time frame: From enrollment until 1 year or time of permanent discontinuation of abemaciclib, which ever comes first

Secondary outcomes

  1. Persistence rate

    Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)

    Time frame: At 6 and 12 months after therapy start

  2. Satisfaction with Information about Medicines Scale (SIMS-D)

    This scale assess the patient´s knowledge about their treatment. The total score ranges from 0 to 17, with higher scores indicating a higher degree of overall satisfaction with information received.

    Time frame: At 6 and 12 months after therapy start

  3. Medication Adherence Rate Scale (MARS-D)

    A total score ranges from 5 to 25 for adherence with higher scores indicating higher self-treported adherence.

    Time frame: At 6 and 12 months after therapy start

  4. Bloem's patient typology questionnaire

    This 6-item instrument classifies patients into four segments: 1) High Acceptance / High Control (Active/Adjusted): Good mental, low care need. 2) Low Acceptance / High Control (Struggling/Active): High need for support to accept the situation. 3) High Acceptance / Low Control (Resigned/Passive): High need for educational/proactive support. 4) Low Acceptance / Low Control (Vulnerable/Anxious): Highest care need, requires intense supportive care.

    Time frame: At 6 and 12 months after therapy start

07

Study locations

8 of 8 sites recruiting
  • Klinikum Esslingen, Frauenheilkunde und Geburtshilfe
    Esslingen am Neckar, Baden-Wurttemberg 73730, Germany
    Recruiting
  • MVZ am Klinikum Aschaffenburg GmbH
    Aschaffenburg, Bavaria 63739, Germany
    Recruiting
  • Department of Obstetrics and Gynaecology
    Erlangen, Bavaria 91054, Germany
    Recruiting
  • Klinikum Kulmbach, Brustzentrum
    Kulmbach, Bavaria 95326, Germany
    Recruiting
  • MVZ für Onkologie und Urologie GmbH
    Wilhelmshaven, Lower Saxony 26389, Germany
    Recruiting
  • Evangelisches Klinikum Bergisch Gladbach, Gynäkologie
    Bergisch Gladbach, North Rhine-Westphalia 51465, Germany
    Recruiting
  • Klinikum Itzehoe, Holsteinisches Brustzentrum
    Itzehoe, Schleswig-Holstein 25524, Germany
    Recruiting
  • Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie)
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jun 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 9, 2026
StartActual
Jun 19, 2026was Oct 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
7 sites added. Department of Obstetrics and Gynaecology is now Recruiting
Show 7 added (7 Germany)
  • Klinikum Esslingen, Frauenheilkunde und Geburtshilfe · Esslingen am Neckar, Germany
  • MVZ am Klinikum Aschaffenburg GmbH · Aschaffenburg, Germany
  • Klinikum Kulmbach, Brustzentrum · Kulmbach, Germany
  • MVZ für Onkologie und Urologie GmbH · Wilhelmshaven, Germany
  • Evangelisches Klinikum Bergisch Gladbach, Gynäkologie · Bergisch Gladbach, Germany
  • Klinikum Itzehoe, Holsteinisches Brustzentrum · Itzehoe, Germany
  • Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) · Lübeck, Germany
Nov 4, 2026
Start date
Oct 2026→Jun 19, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    7 sites added. Department of Obstetrics and Gynaecology is now Recruiting
    Show 7 added (7 Germany)
    • Klinikum Esslingen, Frauenheilkunde und Geburtshilfe · Esslingen am Neckar, Germany
    • MVZ am Klinikum Aschaffenburg GmbH · Aschaffenburg, Germany
    • Klinikum Kulmbach, Brustzentrum · Kulmbach, Germany
    • MVZ für Onkologie und Urologie GmbH · Wilhelmshaven, Germany
    • Evangelisches Klinikum Bergisch Gladbach, Gynäkologie · Bergisch Gladbach, Germany
    • Klinikum Itzehoe, Holsteinisches Brustzentrum · Itzehoe, Germany
    • Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) · Lübeck, Germany
    Start date Oct 2026→Jun 19, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07521202
Lead sponsor
Institut fuer Frauengesundheit
Collaborators
Lilly Deutschland GmbH Germany
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jun 19, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Sponsor's study office
Contact
studien@ifg-erlangen.de
+49 15739466438
Peter A. Fasching, Prof. Dr. med.
study chair · Department of Obstetrics and Gynaecology, Uniklinikum Erlangen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion